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withdrawn in patient 1 and reduced (budesdonide from 15 to
5mg) in patient 2. Mononuclear cells were analyzed by ﬂow
cytometry before and after IL-2 in patients and healthy
donors. Treg subsets were determined within the CD4+ T cell
population to identify thymus-derived natural Treg (nTreg)
and induced Treg (iTreg). NK cell subsets were determined
within CD56+CD3- population to identify CD56bright,
CD56dimNKG2A+KIR-, and CD56dim KIR+CD57+ NK cells.
Functional analysis was performed by isolating Treg
(CD3+CD4+CD25hiCD127dim), conventional T cells (Tcon:
CD3+CD4+CD25loCD127hi) and NK cells (CD3-CD56+). Treg
function was measured by suppression of CD154 expression
on Tcon stimulated with CD3/CD28 beads. NK cell function
was measured by K562 killing. Healthy volunteers showed
a signiﬁcant increase in both nTreg and iTreg by 2-3 fold
(p¼0.0003) and CD56bright NK cells by 1.2-1.8 fold in 7 days
after the initial dose of IL-2 (p¼0.02). In patients, the fraction
of nTreg increased above baseline by 1.2-1.4 fold while iTreg
decreased. NK cells showed marked expansion of CD56bright
NK cells within 2 weeks of treatment, with no change in
CD56dimNKG2A+KIR-, and CD56dimKIR+CD57+ NK cells.
Functional assays demonstrated increased Treg suppression
of autologous Tcon and NK cell killing of K562 after IL-2
treatment in both patients. These ﬁndings indicate that ultra
low dose IL-2 causes expansion of natural Treg and NK cells
resulting in greater suppressive activity and K562 killing
activity correlating with an improvement in cGVHD for
steroid refractory patients.
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The favorable outcome of umbilical cord blood trans-
plantation (UCBT) is compromised by prolonged time to
engraftment, delayed immunologic reconstitution and late
memory T cell skewing. Studies in zebraﬁsh and mice have
shown that the prostaglandin compound, 16,16 dimethyl
prostaglandin E2 (PGE2) increases HSC engraftment. We
performed a Phase Ib clinical trial of double UCBT (dUCBT)
using one untreated and one ex vivo PGE2-treated UCB unit
to determine safety and engraftment. 12 subjects with
hematologic malignancies were enrolled. The PGE2-UCB was
the dominant source of hematopoiesis in 10 of 12 subjects
with full T cell chimerism detected as early as 13 days. In UCB
T cells, PGE2 mediated increase of intracellular cAMP, acti-
vation of PKA and modulated the Wnt/b-catenin pathway as
determined by upregulation of b-catenin and expression of
Wnt target genes Lef1, Tcf7 and Runx1. PGE2 inhibited
proliferation of UCB T cells in response to stimulation via
CD3/CD28 and resulted in high expression of IL-7 receptor
(CD127). Assessment of T cell reconstitution indicated that
during the ﬁrst year, the numbers of total T cells (CD3+), CD4+
and CD8+ T subsets remained signiﬁcantly lower (p¼0.036)
in PGE2-UCBT recipients compared to dUCBT recipients
without PGE2. To examine whether PGE2-mediated Wnt/b-
catenin imprinting might be evident in PGE2-UCBT recipi-
ents, we examined expression of the Wnt/b-catenin target
Eomes, a transcription factor that links the long-term
memory CD8+ T cells to effector potency and protective
immunity. Expression of Eomes was signiﬁcantly elevated in
PBMCs of PGE2-UCBT recipients compared to controls.
Consistent with the role of Wnt/b-catenin to maintain
a central memory/stem cell memory CD8+ phenotype, there
was an increased fraction of CD8+CD62L+ cells in recipients of
PGE2-UCBT in contrast to the late memory T cell skewing in
dUCBT recipients without PGE2. Moreover, PGE2-UCBT
recipients displayed potent antiviral immunity resulting in
a reduced incidence of CMV viremia and no EBV-mediated
posttransplant lymphoproliferative disorder. Our ﬁndings
indicate that PGE2-UCB treatment induces Wnt-mediated
gene programming and might favor the generation of long-
lived memory CD8+ T cells.71
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Graft-versus-host disease (GVHD) is a detrimental
complication of allogeneic hematopoietic cell trans-
plantation (HCT) associatedwith impaired quality-of-life and
decreased overall survival. Methods for predicting GVHD
may enable use of pre-emptive therapeutic maneuvers to
prevent or diminish clinical GVHD symptoms. Studies of
GVHD in murine allograft models have shown that GVH
reactions are associated with structural and functional
derangements of lymphoid tissues, including lymph nodes,
spleen, thymus, and bone marrow. Because these organs
